Values as of: 2024-10-04
COMMON STOCK | Medical Devices |
Last Closing
USD 6.25Change
0.00 (0.00)%Market Cap
USD 2.74BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Company Website : https://elekta.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 67.29B |
| SMMNY | Siemens Healthineers AG ADR |
N/A |
USD 67.05B |
| RYLPF | Koninklijke Philips N.V |
+1.33 (+4.36%) |
USD 29.26B |
| SONVF | Sonova Holding AG |
-0.65 (-0.18%) |
USD 21.33B |
| WILLF | Demant A/S |
N/A |
USD 8.81B |
| GNGBF | Getinge AB |
N/A |
USD 5.86B |
| AMBBY | Ambu A/S |
N/A |
USD 5.19B |
| AMBFF | Ambu A/S |
N/A |
USD 5.19B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.66B |
| GNNDY | GN Store Nord A/S ADR |
N/A |
USD 3.45B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -23.31% | 42% | F | 30% | F | ||
| Dividend Return | 2.85% | 83% | B | 44% | F | ||
| Total Return | -20.46% | 43% | F | 31% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -11.35% | 56% | F | 42% | F | ||
| Dividend Return | 3.30% | 85% | B | 46% | F | ||
| Total Return | -8.05% | 56% | F | 43% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -49.60% | 52% | F | 38% | F | ||
| Dividend Return | 21.58% | 92% | A | 66% | D+ | ||
| Total Return | -28.02% | 64% | D | 45% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -3.26% | N/A | N/A | 32% | F | ||
| Dividend Return | 2.46% | N/A | N/A | 39% | F | ||
| Total Return | 5.72% | N/A | N/A | 77% | C+ | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 34.67% | N/A | N/A | 66% | D+ | ||
| Risk Adjusted Return | 7.10% | N/A | N/A | 41% | F | ||
| Market Capitalization | 2.74B | 90% | A- | 81% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
